The aims of the UCSF-GIVI CFAR are to support a multi-disciplinary environment that promotes basic, clinical, epidemiologic, behavioral, and translational research in the prevention, detection, and treatment of HIV infection and AIDS and to further the programs of NIH institutes by providing unique and effectively managed activities propelling HIV research. CFAR applies effective leadership, open communications, educational opportunities, sound resource management, and strategic planning to link CFAR members across sites and scientific disciplines. The Center's leadership is committed to proactive management, transparency and continued program monitoring, evaluation, and readjustment. CFAR maintains an effective partnership with the UCSF AIDS Research Institute and with the Center for AIDS Prevention Studies. To catalyze multidisciplinary research, the Center manages six scientific cores (Clinical and Population Sciences, Immunology, Virology, Specimen Banking, Pharmacology, and International). The Clinical and Population Sciences Core facilitates access to appropriate clinical cohorts. The International Core, focused on a growing portfolio in Uganda, will build in-country capacity and collaborate with the Fogarty International Center in training. Expansion to other African sites is expected. Core Directors are charged with member outreach and soliciting new investigators to take advantage of the cutting edge technologies and assays available within the cores. Success of the scientific cores is assessed by the quality of the multidisciplinary science they stimulate and by the publications and successful grants to which they contribute. The CFAR Administrative Core maintains an electronic network, including videoconferencing, to connect and inform all CFAR members, organizes scientific seminars and symposia, and implements financial systems to monitor and report all CFAR funds, ensuring maximum CFAR effectiveness. The Developmental Core funds pilot and basic science grants. It supports the next generation of HIV science through mentored pilot grants and an extremely successful and ambitious formal mentoring program. The success of the UCSF-GIVI CFAR is evident in the scientific accomplishments of its investigators, its ability to galvanize fundamentally new science through its focus on innovative multidisciplinary HIV research, and the significant institutional support it receives from UCSF, the San Francisco Veterans Affairs Medical Center and the J. David Gladstone Institutes.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Center Core Grants (P30)
Project #
3P30AI027763-20S1
Application #
8332443
Study Section
Special Emphasis Panel (ZAI1-EC-A (J1))
Program Officer
Namkung, Ann S
Project Start
1997-03-01
Project End
Budget Start
2011-09-15
Budget End
2012-08-31
Support Year
20
Fiscal Year
2011
Total Cost
$123,804
Indirect Cost
Name
University of California San Francisco
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Elion, Richard A; Althoff, Keri N; Zhang, Jinbing et al. (2018) Recent Abacavir Use Increases Risk of Type 1 and Type 2 Myocardial Infarctions Among Adults With HIV. J Acquir Immune Defic Syndr 78:62-72
Scherzer, Rebecca; Shah, Sanjiv J; Secemsky, Eric et al. (2018) Association of Biomarker Clusters With Cardiac Phenotypes and Mortality in Patients With HIV Infection. Circ Heart Fail 11:e004312
Shehata, Hesham M; Khan, Shahzada; Chen, Elise et al. (2018) Lack of Sprouty 1 and 2 enhances survival of effector CD8+ T cells and yields more protective memory cells. Proc Natl Acad Sci U S A 115:E8939-E8947
Tang, Eric C; Vittinghoff, Eric; Anderson, Peter L et al. (2018) Changes in Kidney Function Associated With Daily Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Preexposure Prophylaxis Use in the United States Demonstration Project. J Acquir Immune Defic Syndr 77:193-198
Hosseinipour, Mina C; Kang, Minhee; Krown, Susan E et al. (2018) As-Needed Vs Immediate Etoposide Chemotherapy in Combination With Antiretroviral Therapy for Mild-to-Moderate AIDS-Associated Kaposi Sarcoma in Resource-Limited Settings: A5264/AMC-067 Randomized Clinical Trial. Clin Infect Dis 67:251-260
Yoon, Christina; Semitala, Fred C; Asege, Lucy et al. (2018) Yield and Efficiency of Novel Intensified Tuberculosis Case-Finding Algorithms for People Living with HIV. Am J Respir Crit Care Med :
Tang, Weiming; Liu, Chuncheng; Cao, Bolin et al. (2018) Receiving HIV Serostatus Disclosure from Partners Before Sex: Results from an Online Survey of Chinese Men Who Have Sex with Men. AIDS Behav 22:3826-3835
Ayers, Leona W; Barbachano-Guerrero, Arturo; McAllister, Shane C et al. (2018) Mast Cell Activation and KSHV Infection in Kaposi Sarcoma. Clin Cancer Res 24:5085-5097
Tamraz, Bani; Huang, Yong; French, Audrey L et al. (2018) A Genome-Wide Association Study Identifies a Candidate Gene Associated With Atazanavir Exposure Measured in Hair. Clin Pharmacol Ther 104:949-956
Clutton, Genevieve Tyndale; Jones, R Brad (2018) Diverse Impacts of HIV Latency-Reversing Agents on CD8+ T-Cell Function: Implications for HIV Cure. Front Immunol 9:1452

Showing the most recent 10 out of 1541 publications